CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 45 enrolled
Drug / intervention
Immunotherapy (physician's choice for standard of care immunotherapy) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03176173
NCT03176173N/ACompleted
CompareCT.gov

Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy

Stanford University·interventional·Posted Jun 5, 2017·Updated Nov 5, 2025

In Brief

A clinical study evaluating Image-guided Radiation Therapy and Immunotherapy (physician's choice for standard of care immunotherapy) for Stage IV Non-Small Cell Lung Cancer. Completed, enrolled 45 participants across 1 site.

Detailed Summary

This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with non-small cell lung cancer may help to improve response to immunotherapy anti-cancer treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IV Non-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsVarian Medical Systems

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJun 5, 2017
Enrollment StartJun 28, 2017
Primary CompletionNov 24, 2021
Study CompletionJan 31, 2025
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.1 years ago

Interventions

Image-guided Radiation Therapyradiation

Ablative treatment as 50 Gy in 5 or 10 fractions. Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions.

Immunotherapy (physician's choice for standard of care immunotherapy)drug

Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.